Department of Anesthesiology and Intensive Care Medicine, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, 467-8601, Japan.
Scientific Research WorkS Peer Support Group (SRWS-PSG), Osaka, Japan.
J Anesth. 2023 Jun;37(3):416-425. doi: 10.1007/s00540-023-03183-7. Epub 2023 Mar 25.
Intravenous dexamethasone is recommended in elective caesarean delivery to decrease postoperative pain. However, the efficacy of spinal anaesthesia with an intrathecal long-acting opioid such as morphine or diamorphine for caesarean delivery has not been systematically investigated.
We searched all randomized controlled trials (RCTs) of pregnant women undergoing caesarean delivery under spinal anaesthesia with an intrathecal morphine or diamorphine via MEDLINE, CENTRAL, EMBASE, ICTRP, and ClinicalTrials.gov on May 18, 2022. Primary outcomes were time to first rescue analgesia, consumption of oral morphine equivalents, and incidence of drug-related adverse reactions. We evaluated the risk of bias for each outcome using the Risk of Bias 2. We conducted a meta-analysis using a random effects model. We evaluated the certainty of evidence with the GRADE approach.
Five RCTs (455 patients) were included. The results of intravenous dexamethasone were as follows: time to first rescue analgesia (mean difference [MD] 0.99 h, 95% confidence interval [CI] - 0.86 to 2.84; very low certainty) and consumption of oral morphine equivalents (MD - 6.55 mg, 95% CI - 17.13 to 4.02; moderate certainty). No incidence of drug-related adverse reactions was reported (very low certainty).
The evidence was very uncertain about the efficacy of intravenous dexamethasone on time to first rescue analgesia and the incidence of drug-related adverse reactions. Intravenous dexamethasone probably reduces the consumption of oral morphine equivalents. Anaesthesiologists might want to consider intravenous dexamethasone for postoperative pain after caesarean delivery under spinal anaesthesia with an intrathecal long-acting opioid.
在择期剖宫产中,推荐静脉给予地塞米松以减轻术后疼痛。然而,椎管内麻醉中使用长效阿片类药物(如吗啡或二氢吗啡酮)行剖宫产术的效果尚未得到系统研究。
我们于 2022 年 5 月 18 日通过 MEDLINE、CENTRAL、EMBASE、ICTRP 和 ClinicalTrials.gov 检索了所有关于椎管内麻醉中使用吗啡或二氢吗啡酮行剖宫产术的随机对照试验(RCT)。主要结局为首次解救镇痛的时间、口服吗啡等效物的消耗量和药物相关不良反应的发生率。我们使用风险偏倚 2 工具评估了每个结局的风险偏倚。我们使用随机效应模型进行荟萃分析。我们使用 GRADE 方法评估证据的确定性。
纳入了 5 项 RCT(455 名患者)。静脉给予地塞米松的结果如下:首次解救镇痛的时间(均数差值 [MD] 0.99 小时,95%置信区间 [CI] -0.86 至 2.84;极低确定性)和口服吗啡等效物的消耗量(MD -6.55 毫克,95% CI -17.13 至 4.02;中等确定性)。未报告药物相关不良反应的发生率(极低确定性)。
关于静脉给予地塞米松对首次解救镇痛时间和药物相关不良反应发生率的疗效,证据极不确定。静脉给予地塞米松可能减少口服吗啡等效物的消耗量。椎管内麻醉中使用长效阿片类药物行剖宫产术时,麻醉医师可能需要考虑使用静脉给予地塞米松以缓解术后疼痛。